A second update of the recommendations for the practical stability of anticancer drugs published in 2013 has been realized by the French Society of Hospital Pharmacists (SFPO); European Society of Oncology Pharmacists (ESOP); and members of the Stabilis® database (www.stabilis.org), a stability and compatibility database of drugs. Forty-six new molecules have been included. These new data make it possible to optimize anticancer drug preparations and achieve product savings. These new recommendations have to be taken into consideration only if the preparation is made according to the Good Manufacturing Practices in classified rooms.